E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group

Shanthi Marur, Shuli Li, Anthony J. Cmelak, +14

Journal of Clinical Oncology

Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

Joseph A. Califano, Zubair Khan, Kimberly Noonan, +19

Clinical Cancer Research

Neoadjuvant TherapyImmunologyPde5 InhibitorPathologyImmunoediting +16

Association between severe treatment‐related lymphopenia and progression‐free survival in patients with newly diagnosed squamous cell head and neck cancer

Jian Campian, Guneet Sarai, Xiaobu Ye, +2

Head & Neck

Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma

Julie Ann Sosa, Rossella Elisei, Barbara Jarząb, +14

Thyroid

Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer

Giuseppe Sanguineti, Maria Pia Sormani, Shanthi Marur, +7

International Journal of Radiation Oncology*Biology*Physics

Intensity-modulated Radiation TherapyRadiation TherapyMedicineOropharyngeal CancerHead And Neck Squamous Cell Carcinoma +5

Multidisciplinary head and neck cancer clinic and adherence with speech pathology

Heather M. Starmer, Giuseppe Sanguineti, Shanthi Marur, +1

The Laryngoscope

Volumetric Change of Selected Organs at Risk During IMRT for Oropharyngeal Cancer

Francesco Ricchetti, Binbin Wu, Todd McNutt, +5

International Journal of Radiation Oncology*Biology*Physics

Volumetric ChangeMedicineSelected OrgansOropharyngeal CancerLarynx +7

Impact of surgeon and hospital volume on short‐term outcomes and cost of laryngeal cancer surgical care

Christine G. Gourin, Arlene A. Forastiere, Giuseppe Sanguineti, +3

The Laryngoscope

E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).

Anthony J. Cmelak, Shuli Li, Shanthi Marur, +12

Journal of Clinical Oncology

Surgical OncologyPathologyTreatment ResistanceCancer-associated VirusOncology +16

A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.

Julie Ann Sosa, Rossella Elisei, Barbara Jarząb, +15

Journal of Clinical Oncology